Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder

Acta Oncologica

Volumn 47, Issue 5, 2008, Pages 937-940

  Poortmans, Philip M ^a   Richaud, Pierre ^b   Collette, Laurence ^c   Ho Goey, S ^d   Pierart, Marianne ^c   Van Der Hulst, Marleen ^a   Bolla, Michel ^e  

^a DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^b INSTITUT BERGONIÉ   (France)

^c EORTC DATA CENTER   (Belgium)

^d CPRLab   (Netherlands)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; FATIGUE; FOLLOW UP; HEMATURIA; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; RADIATION DOSE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; URETHRA STENOSIS; URINARY TRACT INFECTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, MUSCLE TISSUE; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 45849102115     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860801888799     Document Type: Article

References (24)

1. Scher HI. New approaches to the treatment of bladder cancer. N Engl J Med 1993;329:1420-1.
2. Widmark A, Flodgren P, Damber JE, Hellsten S, Cavallin-Stahl E. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 2003;42:567-81.
3. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:189-201.
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48:202-6.
5. Arias F, Dominguez MA, Martinez E, Illarramendi JJ, Miquelez S, Pascual I, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000;47:373-8.
6. Arias F, Duenas M, Martinez E, Dominguez MA, Illarramendi JJ, Villafranca E, et al. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle. Cancer 1997;80:115-20.
7. Chauvet B, Davin JL, Alfonsi M, Berger C, Vincent P, Reboul F. Conservative treatment of bladder cancers with radiotherapy and concurrent chemotherapy: Results and perspectives. Cancer Radiother 1998;2:499-504.
8. George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 2004;64:488-93.
9. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665-72.
10. Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J Clin Oncol 1993;11:2150-7.
11. Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DM, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer 2004;90:2106-11.
12. Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre B, Zerbib M. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: Report of a single institution. Urology 2004;63:73-7.
13. Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 2005;61:420-5.
14. Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates - the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005;15:36-41.
15. Sumiyoshi Y. Chemoradiotherapy as a bladder-preservation approach for muscle-invasive bladder cancer: Current status and perspectives. Int J Clin Oncol 2004;9:484-90.
16. Venturini M, Merlano M, Michelotti A, Martorana G, Curotto A, Scarpati D, et al. Neoadjuvant or definitive alternating chemotherapy and radiotherapy for infiltrating bladder cancer. Am J Clin Oncol 1989;12:63-7.
17. Bolla M. A phase II feasibility study of combined accelerated external radiation and chemotherapy with 5FU and cisplatin following transurethral resection in patients with muscle invasive transitional carcinoma of the bladder T2-T3, N0, M0 (UICC 1992). EORTC trial 22971. EORTC Data Center, Brussels, 1998.
18. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. ICRU Report 50. Bethesda, 1993.
19. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-83.
20. Coppin CM, Gospodarowicz MK, James K, Tannock I, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901-7.
21. Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:197-207.
22. Majewski W, Maciejewski B, Majewski S, Suwinski R, Miszcyk L, Tarnawski R. Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 2004;60:60-70.
23. Pos FJ, Hart G, Schneider C, Sminia P. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64:1168-73.
24. Milosevic M, Gospodarowicz M, Zietman A, Abbas F, Haustermans K, Moonen L, et al. Radiotherapy for bladder cancer. Urology 2007;69(Suppl):80-92.